Exact Sciences Stock - Analyst sentiment and technical picture on Thursday

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 18:58 CET. Details in the imprint.

Exact Sciences (US30063P1057) is one of the more closely watched US diagnostics names on the Nasdaq. On Thursday the focus is on where the shares sit technically after a strong run and how that aligns with current analyst expectations, based on recent market data.

What recent data show

Exact Sciences is a molecular diagnostics group focused on cancer screening and monitoring, best known for its Cologuard stool-based colorectal test and the Oncotype DX breast cancer assay. The company generated 2024 revenue of around $2.7 billion, with double-digit growth over the prior year.

According to a recent market overview, Exact Sciences carries a market capitalization of roughly $20 billion at a share price a little above $100. This places the stock firmly in mid-cap territory within the US healthcare and life sciences universe, alongside other diagnostics and tools names.

Analyst consensus on the stock

Analyst sentiment on Exact Sciences is mixed but generally constructive. MarketBeat data show a consensus rating of "Reduce" based on several recent broker opinions, while the average 12-month price target stands near $92 per share. That implies downside from current trading levels.

Within that distribution, a number of houses still rate the stock at Buy or Outperform, citing the company’s leading position in colorectal cancer screening and growing presence in multi-cancer early detection. Others remain cautious, pointing to valuation and the competitive landscape in cancer diagnostics.

Chart picture and 200-day line

On Thursday, Exact Sciences shares trade close to the upper end of their 52-week range between about $38.80 and $105, according to recent quote data. The stock thus reflects a strong recovery from last year’s lows, which were well below $50.

Trading data also suggest the shares are changing hands above their 50-day range midpoint and well ahead of longer-term moving averages, indicating a robust upward trend. Chart watchers will note that pullbacks toward these moving averages could test whether the recent strength has lasting support from buyers.

The product behind the stock

Exact Sciences makes most of its revenue from cancer diagnostics, in particular the Cologuard stool-based DNA test for colorectal cancer screening and the Oncotype DX genomic test that helps guide treatment in breast cancer. The company is also investing in multi-cancer blood tests to broaden its long-term growth drivers.

Where the stock trades today

The shares of Exact Sciences (US30063P1057) trade on the Nasdaq at approximately $104.91 as of 06/18/2026, 18:58 CET, based on the latest available market data converted to Central European Time.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.